<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555671</url>
  </required_header>
  <id_info>
    <org_study_id>02-11-11-Rev-1</org_study_id>
    <nct_id>NCT01555671</nct_id>
  </id_info>
  <brief_title>Study of the Effectiveness of Administration of Meperidine on the Length of Active Phase of Labor in Women</brief_title>
  <official_title>Is There Any Effect of Meperidine on the Length of Duration of Labor? A Prospective Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanuni Sultan Suleyman Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanuni Sultan Suleyman Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of meperidine on the length of active phase of labor&#xD;
      in nulliparous or multiparous women, who will be randomized into two (control and study)&#xD;
      groups. Our hypothesis is that the use of meperidine during active labor has no effect on the&#xD;
      duration of labor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Our aim is to examine the effect of the opioid derivative meperidine used during labor&#xD;
           on the duration of labor in singleton pregnancies.&#xD;
&#xD;
        -  The sample size was calculated using the Number Cruncher Statistical System (NCSS) /&#xD;
           PASS 2007. Power 80% and significance level (α) 0.05, the mean (mean) ± standard&#xD;
           deviation (SD) of the first 20 individuals included in the control group of the study&#xD;
           (296.04 ± 170.02) and has minimal clinical significance for the active phase of labor&#xD;
           from previous studies. We found that the sample size should be 200 (100/100) considering&#xD;
           the duration (30 minutes).&#xD;
&#xD;
        -  A Simple randomisation using a random-number table was performed by the independent&#xD;
           nurse staff, who took no further part in the study.Using the sealed envelope technique,&#xD;
           parturients were randomly allocated to two groups: A meperidine group and B normal&#xD;
           saline group&#xD;
&#xD;
        -  Age, height, weight, body mass index (BMI), gravida, parity, week of gestation, expected&#xD;
           fetal weight (EFW), hemoglobin (Hb) and hematocrit (Hct) values and episiotomy&#xD;
           requirements were recorded in two groups.Gender, birth weight, 1st and 5th minute Apgar&#xD;
           scores and presence of meconium aspiration of the newborns in two groups were recorded.&#xD;
&#xD;
        -  During labor, oxytocin induction was not performed during the latent phase in accordance&#xD;
           with the routine protocol of our hospital. Pregnant women in both groups were given&#xD;
           oxytocin (Synpitan® amp) at a concentration of 1% by 10 drops/min by performing&#xD;
           amniotomy when Bishop score was 6 or cervix dilation was 4 cm and when 70% effacement&#xD;
           was achieved. In the meperidine group, when the cervical opening was 6 cm and 70%&#xD;
           washout, 25 mg iv bolus injection of meperidine (2.5 ml) was administered. The same&#xD;
           amount (2.5 ml) of physiological saline was administered intravenously to the subjects&#xD;
           in the control group. The patients were followed in NST until 10 cm clearance and 100%&#xD;
           effacement. This time was recorded as active phase time. The time from the end of the&#xD;
           active phase period to the birth of the baby was recorded as the duration of the second&#xD;
           phase of birth.&#xD;
&#xD;
        -  The primary outcome of interest in this study is the duration of active phase of labor .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Actual">July 1, 2015</completion_date>
  <primary_completion_date type="Actual">May 1, 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized parallel double blind plasebo controlled study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Both drug provider and patient do not know which drug or placebo was given</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The Duration of Active Phase of Labour</measure>
    <time_frame>24h</time_frame>
    <description>The primary outcome is to evaluate whether meperidine is effective in shortening the duration of the active phase of labor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Duration of Labour</measure>
    <time_frame>24h</time_frame>
    <description>Total time of delivery of patients who gave birth including the second stage of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the Second Stage of Labour</measure>
    <time_frame>24h</time_frame>
    <description>The period of time until the birth of the baby, since the patient being followed for delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Labor Pain</condition>
  <arm_group>
    <arm_group_label>meperidine administration group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .Providers and patients were blinded to the contents of the bags until the conclusion of the study. Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>plasebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bag B (placebo group), containing 0.5ml of normal saline solution. Providers and patients were blinded to the contents of the bags until the conclusion of the study.Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meperidine</intervention_name>
    <description>0.5 ml meperidine injection intravenously injected in randomly selected patients</description>
    <arm_group_label>meperidine administration group</arm_group_label>
    <other_name>Aldolan 100 mg/2 ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.5 ml saline solution injection intravenously injected in randomly selected patients</description>
    <arm_group_label>plasebo group</arm_group_label>
    <other_name>0.90% w/v of NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  gestational age between 38 and 42 weeks&#xD;
&#xD;
          -  live fetus&#xD;
&#xD;
          -  cephalic presentation&#xD;
&#xD;
          -  in active phase of labour&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  placenta previa, placental abruption&#xD;
&#xD;
          -  caesarean section or any uterine scarring&#xD;
&#xD;
          -  multiple gestation&#xD;
&#xD;
          -  fetal macrosomia (≥4000 g)&#xD;
&#xD;
          -  meperidine allergy&#xD;
&#xD;
          -  use any kind of labour induction or augmentation before on admission for delivery in&#xD;
             our hospital&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orhan SAHIN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ministery of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prof.Dr.Cemil Tascioglu City Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34384</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>meperidine,duration of labor,induction of labor</description>
  </link>
  <results_reference>
    <citation>Leong WL, Sng BL, Sia AT. A comparison between remifentanil and meperidine for labor analgesia: a systematic review. Anesth Analg. 2011 Oct;113(4):818-25. doi: 10.1213/ANE.0b013e3182289fe9. Epub 2011 Sep 2. Review.</citation>
    <PMID>21890889</PMID>
  </results_reference>
  <results_reference>
    <citation>Sica-Blanco Y, Rozada H, Remedio MR. Effect of meperidine on uterine contractility during pregnancy and prelabor. Am J Obstet Gynecol. 1967 Apr 15;97(8):1096-100.</citation>
    <PMID>6021289</PMID>
  </results_reference>
  <results_reference>
    <citation>Sosa CG, Balaguer E, Alonso JG, Panizza R, Laborde A, Berrondo C. Meperidine for dystocia during the first stage of labor: A randomized controlled trial. Am J Obstet Gynecol. 2004 Oct;191(4):1212-8.</citation>
    <PMID>15507943</PMID>
  </results_reference>
  <results_reference>
    <citation>Sosa CG, Buekens P, Hughes JM, Balaguer E, Sotero G, Panizza R, Piriz H, Alonso JG. Effect of pethidine administered during the first stage of labor on the acid-base status at birth. Eur J Obstet Gynecol Reprod Biol. 2006 Dec;129(2):135-9. Epub 2006 Jan 6.</citation>
    <PMID>16406273</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <results_first_submitted>May 28, 2021</results_first_submitted>
  <results_first_submitted_qc>September 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2021</results_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanuni Sultan Suleyman Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Orhan SAHIN, M.D.</investigator_full_name>
    <investigator_title>MD,</investigator_title>
  </responsible_party>
  <keyword>labor,</keyword>
  <keyword>meperidine,</keyword>
  <keyword>active phase,</keyword>
  <keyword>duration of labor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meperidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was planned to be carried out between January 2012 and May 2012 in Kanuni Sultan Süleyman training and research hospital(Istanbul-Turkey), gynecology and obstetrics department.</recruitment_details>
      <pre_assignment_details>A total of 449 patients were included in the study. 199 patients who did not meet the inclusion criteria were excluded from the study. The remaining 250 patients were randomized to the groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Group</title>
          <description>Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine,0.5ml (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Bag B (placebo group), containing 0.5ml of normal saline solution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>term pregnancies with active labor</population>
      <group_list>
        <group group_id="B1">
          <title>Study Group</title>
          <description>0.5 ml meperidine injection intravenously injected in randomly selected patients</description>
        </group>
        <group group_id="B2">
          <title>Plasebo Group</title>
          <description>0.5 ml saline solution injection intravenously injected in randomly selected patients</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="125"/>
                    <count group_id="B2" value="125"/>
                    <count group_id="B3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Of the 250 patients included in the study, 45 patients with cesarean indication were excluded from the study and baseline measurements were made on the remaining patient population.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="105"/>
                    <count group_id="B2" value="100"/>
                    <count group_id="B3" value="205"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.21" spread="5.17"/>
                    <measurement group_id="B2" value="26.03" spread="4.8"/>
                    <measurement group_id="B3" value="25.83" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="125"/>
                    <count group_id="B2" value="125"/>
                    <count group_id="B3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="125"/>
                    <count group_id="B2" value="125"/>
                    <count group_id="B3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Duration of Active Phase of Labour</title>
        <description>The primary outcome is to evaluate whether meperidine is effective in shortening the duration of the active phase of labor</description>
        <time_frame>24h</time_frame>
        <population>women giving birth at term period</population>
        <group_list>
          <group group_id="O1">
            <title>Meperidine Administration Group</title>
            <description>Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .Providers and patients were blinded to the contents of the bags until the conclusion of the study. Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.&#xD;
Meperidine: 0.5 ml meperidine injection intravenously injected in randomly selected patients</description>
          </group>
          <group group_id="O2">
            <title>Plasebo Group</title>
            <description>Bag B (placebo group), containing 0.5ml of normal saline solution. Providers and patients were blinded to the contents of the bags until the conclusion of the study.Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.&#xD;
Saline: 0.5 ml saline solution injection intravenously injected in randomly selected patients</description>
          </group>
        </group_list>
        <measure>
          <title>The Duration of Active Phase of Labour</title>
          <description>The primary outcome is to evaluate whether meperidine is effective in shortening the duration of the active phase of labor</description>
          <population>women giving birth at term period</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249" spread="122"/>
                    <measurement group_id="O2" value="304" spread="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>30</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Duration of Labour</title>
        <description>Total time of delivery of patients who gave birth including the second stage of delivery</description>
        <time_frame>24h</time_frame>
        <population>Total time of delivery of patients who gave birth including the second stage of delivery</population>
        <group_list>
          <group group_id="O1">
            <title>Meperidine Administration Group</title>
            <description>Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .Providers and patients were blinded to the contents of the bags until the conclusion of the study. Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.&#xD;
Meperidine: 0.5 ml meperidine injection intravenously injected in randomly selected patients</description>
          </group>
          <group group_id="O2">
            <title>Plasebo Group</title>
            <description>Bag B (placebo group), containing 0.5ml of normal saline solution. Providers and patients were blinded to the contents of the bags until the conclusion of the study.Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.&#xD;
Saline: 0.5 ml saline solution injection intravenously injected in randomly selected patients</description>
          </group>
        </group_list>
        <measure>
          <title>Total Duration of Labour</title>
          <description>Total time of delivery of patients who gave birth including the second stage of delivery</description>
          <population>Total time of delivery of patients who gave birth including the second stage of delivery</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273" spread="129"/>
                    <measurement group_id="O2" value="331" spread="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of the Second Stage of Labour</title>
        <description>The period of time until the birth of the baby, since the patient being followed for delivery</description>
        <time_frame>24h</time_frame>
        <population>duration of the second stage of labour</population>
        <group_list>
          <group group_id="O1">
            <title>Meperidine Administration Group</title>
            <description>Meperidine: 0.5 ml meperidine injection intravenously injected in randomly selected patients</description>
          </group>
          <group group_id="O2">
            <title>Plasebo Group</title>
            <description>Saline: 0.5 ml saline solution injection intravenously injected in randomly selected patients</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of the Second Stage of Labour</title>
          <description>The period of time until the birth of the baby, since the patient being followed for delivery</description>
          <population>duration of the second stage of labour</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="15"/>
                    <measurement group_id="O2" value="27" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24h</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>emezis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Orhan SAHIN</name_or_title>
      <organization>Prof.Dr.Cemil Tascioglu City Hospital</organization>
      <phone>+90 532 240 00 12</phone>
      <email>drorhansahin@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

